Insider accumulation at CalciMedica, Inc. (NASDAQ: CALC) has drawn attention following a substantial acquisition by director Fred A. Middleton. On June 25, 2026, Middleton indirectly acquired 248,972 shares of the company’s common stock through a transaction valued at approximately $199,999. The shares were purchased at $0.8033 per share, a price point that tracks closely with the stock’s recent trading range near $0.82. This activity occurs against a backdrop of significant price compression for CALC over the preceding six months, during which the stock experienced an 86% decline.
The acquisition was facilitated under the terms of a Securities Purchase Agreement dated June 23, 2026, with the closing of the transaction taking place on June 25, 2026. The issuance of these securities and the underlying agreement received formal approval from an independent committee of CalciMedica’s Board of Directors. The purchase was executed through Sanderling Venture Partners VI Co-Investment Fund, L.P., which now holds a total of 1,063,272 shares of CalciMedica common stock following the completion of the transaction.
Middleton’s indirect exposure to CalciMedica extends across multiple investment vehicles. Beyond the newly acquired shares, he holds 946,744 shares through Sanderling Venture Partners VI, LP, 22,479 shares via Sanderling Ventures Management VI, 7,456 shares through Sanderling VI Beteligungs GmbH & Co KG, and 8,884 shares via Sanderling VI Limited Partnership. Additional indirect positions include 435,148 shares held by Sanderling Ventures VII, L.P., 114,260 shares through Sanderling Ventures VII (Canada), L.P., 27,609 shares via Sanderling Ventures VII Annex Fund, L.P., and 30,292 shares through Sanderling Ventures Management VII. Furthermore, 8,176 shares are indirectly held by Golden Triangle Ventures, LLC. Middleton has disclaimed beneficial ownership of these indirectly held securities except to the extent of his pecuniary interest. In addition to these indirect holdings, Middleton directly owns 36,514 shares of CalciMedica common stock.
CalciMedica’s market position remains concentrated, with the company holding a market capitalization of approximately $12.89 million. Analysis suggests the stock may be undervalued at current levels, though the broader market context reflects substantial volatility. The company’s operational trajectory is also being shaped by recent regulatory and financial developments. The U.S. Food and Drug Administration has cleared the continuation of its Phase 2 KOURAGE trial, which evaluates Auxora for patients suffering from Stage 2 or Stage 3 acute kidney injury and associated acute hypoxemic respiratory failure. Enrollment in the study had previously been paused following a recommendation from the Independent Data Monitoring Committee regarding a mortality imbalance.
Concurrently, CalciMedica has entered into a private placement financing agreement capable of raising up to approximately $49 million in gross proceeds. This financing structure involves the sale of units comprising common stock or pre-funded warrants, alongside rights to receive Series A and Series B warrants. Participation in this financing round includes both new investors and existing stakeholders, with members of CalciMedica’s Board of Directors and management team actively involved. These developments underscore a period of strategic adjustment and capital deployment for the company.